tradingkey.logo
tradingkey.logo
Search

Quantum BioPharma Ltd

QNTM
Add to Watchlist
6.940USD
+1.470+26.87%
Market hours ETQuotes delayed by 15 min
40.64MMarket Cap
LossP/E TTM

Quantum BioPharma Ltd

6.940
+1.470+26.87%

More Details of Quantum BioPharma Ltd Company

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

Quantum BioPharma Ltd Info

Ticker SymbolQNTM
Company nameQuantum Biopharma Ltd
IPO dateMay 29, 2018
CEOKotra (Lakshmi P)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endMay 29
Address55 University Ave. , Suite 1003
CityTORONTO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeM5J 2H7
Phone14168548884
Websitehttps://www.quantumbiopharma.com/
Ticker SymbolQNTM
IPO dateMay 29, 2018
CEOKotra (Lakshmi P)

Company Executives of Quantum BioPharma Ltd

Name
Name/Position
Position
Shareholding
Change
Mr. Zeeshan Saeed
Mr. Zeeshan Saeed
Executive Co-Chairman of the Board, President, Chief Executive Officer
Executive Co-Chairman of the Board, President, Chief Executive Officer
348.02K
+32.99%
Mr. Anthony Durkacz
Mr. Anthony Durkacz
Co-Executive Chairman of the Board
Co-Executive Chairman of the Board
258.72K
+44.37%
Mr. Donal Carroll, CPA
Mr. Donal Carroll, CPA
Chief Financial Officer
Chief Financial Officer
114.81K
-100.00%
Mr. Lawrence (Larry) Latowsky
Mr. Lawrence (Larry) Latowsky
Independent Director
Independent Director
--
--
Mr. Adnan Bashir
Mr. Adnan Bashir
Independent Director
Independent Director
--
--
Dr. Lakshmi P. Kotra, Ph.D.
Dr. Lakshmi P. Kotra, Ph.D.
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
--
--
Mr. Joseph L. Romano
Mr. Joseph L. Romano
Director
Director
--
--
Dr. Eric Hoskins, M.D.
Dr. Eric Hoskins, M.D.
Independent Director
Independent Director
--
--
Mr. Michael (Zappy) Zapolin
Mr. Michael (Zappy) Zapolin
Independent Director
Independent Director
--
--
Dr. Andrzej Chruscinski, M.D., Ph.D.
Dr. Andrzej Chruscinski, M.D., Ph.D.
Vice President - Clinical and Scientific Affairs
Vice President - Clinical and Scientific Affairs
--
-100.00%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Zeeshan Saeed
Mr. Zeeshan Saeed
Executive Co-Chairman of the Board, President, Chief Executive Officer
Executive Co-Chairman of the Board, President, Chief Executive Officer
348.02K
+32.99%
Mr. Anthony Durkacz
Mr. Anthony Durkacz
Co-Executive Chairman of the Board
Co-Executive Chairman of the Board
258.72K
+44.37%
Mr. Donal Carroll, CPA
Mr. Donal Carroll, CPA
Chief Financial Officer
Chief Financial Officer
114.81K
-100.00%
Mr. Lawrence (Larry) Latowsky
Mr. Lawrence (Larry) Latowsky
Independent Director
Independent Director
--
--
Mr. Adnan Bashir
Mr. Adnan Bashir
Independent Director
Independent Director
--
--
Dr. Lakshmi P. Kotra, Ph.D.
Dr. Lakshmi P. Kotra, Ph.D.
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
--
--

Revenue Breakdown

Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Wed, May 13
Updated: Wed, May 13
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Malone Wealth Ventures LLC
5.87%
Saeed (Zeeshan)
5.44%
Durkacz (Anthony)
4.04%
Carroll (Donal)
1.79%
AdvisorShares Investments, LLC
1.70%
Other
81.15%
Shareholders
Shareholders
Proportion
Malone Wealth Ventures LLC
5.87%
Saeed (Zeeshan)
5.44%
Durkacz (Anthony)
4.04%
Carroll (Donal)
1.79%
AdvisorShares Investments, LLC
1.70%
Other
81.15%
Shareholder Types
Shareholders
Proportion
Individual Investor
12.84%
Investment Advisor
8.93%
Research Firm
0.35%
Hedge Fund
0.25%
Corporation
0.22%
Other
77.42%

Institutional Shareholding

Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
44
568.64K
8.89%
-641.84K
2025Q4
43
1.11M
29.09%
+170.72K
2025Q3
40
1.17M
30.70%
+254.90K
2025Q2
50
1.04M
35.99%
+612.85K
2025Q1
50
413.46K
17.05%
-229.58K
2024Q4
44
604.87K
28.35%
+138.76K
2024Q3
45
583.17K
30.09%
+414.87K
2024Q2
43
126.91K
14.87%
-21.03K
2024Q1
47
105.72K
14.06%
-57.49K
2023Q4
49
159.35K
26.32%
+20.22K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Malone Wealth Ventures LLC
375.75K
9.67%
-671.40K
-64.12%
Feb 03, 2026
Saeed (Zeeshan)
233.21K
6%
+114.81K
+96.96%
Mar 20, 2026
Durkacz (Anthony)
143.92K
3.7%
+114.81K
+394.33%
Mar 20, 2026
Carroll (Donal)
114.31K
2.94%
+23.89K
+26.43%
Mar 20, 2026
AdvisorShares Investments, LLC
96.25K
2.48%
+59.01K
+158.48%
Dec 31, 2025
Lynch (Terrence)
51.42K
1.32%
+51.42K
--
Aug 14, 2025
Jane Street Capital, L.L.C.
10.89K
0.28%
+10.89K
--
Dec 31, 2025
Kotra (Lakshmi)
29.57K
0.76%
--
--
Aug 14, 2025
Citadel Advisors LLC
15.86K
0.41%
+15.86K
--
Dec 31, 2025
View more

Related ETFs

Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
AdvisorShares Psychedelics ETF
6.05%
AdvisorShares Psychedelics ETF
Proportion6.05%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Date
Ex-dividend Date
Type
Ratio
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
KeyAI